Last reviewed · How we verify
Pneumococcal conjugate vaccine GSK2830929A
Pneumococcal conjugate vaccine GSK2830929A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | Pneumococcal conjugate vaccine GSK2830929A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal conjugate vaccine GSK2830929A CI brief — competitive landscape report
- Pneumococcal conjugate vaccine GSK2830929A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Pneumococcal conjugate vaccine GSK2830929A
What is Pneumococcal conjugate vaccine GSK2830929A?
Pneumococcal conjugate vaccine GSK2830929A is a Biologic drug developed by GlaxoSmithKline.
Who makes Pneumococcal conjugate vaccine GSK2830929A?
Pneumococcal conjugate vaccine GSK2830929A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Pneumococcal conjugate vaccine GSK2830929A in?
Pneumococcal conjugate vaccine GSK2830929A is in Phase 2.